Anne McNicholas

Summary

Country: New Zealand

Publications

  1. ncbi Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006
    Anne McNicholas
    Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand
    Hum Vaccin 3:196-204. 2007
  2. ncbi Surveillance of vaccine breakthrough cases following MeNZB vaccination
    Anne McNicholas
    Meningococcal Vaccine Strategy, Ministry of Health, PO Box 5013, Wellington, New Zealand
    N Z Med J 121:38-46. 2008
  3. ncbi Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years
    Yvonne Galloway
    Ministry of Health, Wellington, New Zealand
    Int J Epidemiol 38:413-8. 2009
  4. ncbi Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease
    Jane O'Hallahan
    Ministry of Health, Wellington, New Zealand
    N Z Med J 122:48-59. 2009
  5. ncbi The risk of simple febrile seizures after immunisation with a new group B meningococcal vaccine, New Zealand
    Paul Stehr-Green
    Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand
    Vaccine 26:739-42. 2008
  6. ncbi The risk of bronchiolitis hospitalisation following administration of a group B meningococcal vaccine in New Zealand
    Paul Stehr-Green
    Department of Epidemiology, University of Washington, Seattle, Washington, USA
    N Z Med J 120:U2746. 2007
  7. ncbi The Intensive Vaccines Monitoring Programme (IVMP): an electronic system to monitor vaccine safety in New Zealand
    Michael V Tatley
    New Zealand Pharmacovigilance Centre, University of Otago, Dunedin, New Zealand
    Vaccine 26:2746-52. 2008
  8. ncbi Prevalence and risk factors for Chlamydia trachomatis infection in female New Zealand university students
    Michael Baker
    Institute of Environmental Science and Research Limited, Porirua
    N Z Med J 118:U1607. 2005

Detail Information

Publications8

  1. ncbi Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006
    Anne McNicholas
    Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand
    Hum Vaccin 3:196-204. 2007
    ..With over three million doses administered to individuals aged under 20 years, the monitoring results provide consistent evidence supporting the vaccine's safety...
  2. ncbi Surveillance of vaccine breakthrough cases following MeNZB vaccination
    Anne McNicholas
    Meningococcal Vaccine Strategy, Ministry of Health, PO Box 5013, Wellington, New Zealand
    N Z Med J 121:38-46. 2008
    ..To describe and investigate epidemic strain serogroup B meningococcal disease in recipients of the meningococcal vaccine, MeNZB...
  3. ncbi Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years
    Yvonne Galloway
    Ministry of Health, Wellington, New Zealand
    Int J Epidemiol 38:413-8. 2009
    ..In July 2004 a strain-specific vaccine was introduced to combat an epidemic of group B meningococcal disease in New Zealand. We estimated the effectiveness of this vaccine in pre-school-aged children...
  4. ncbi Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease
    Jane O'Hallahan
    Ministry of Health, Wellington, New Zealand
    N Z Med J 122:48-59. 2009
    ..This paper summarises the outcomes of this campaign including coverage levels achieved, evidence of vaccine effectiveness and safety, and the strategies used to manage key events and risks that emerged during the campaign...
  5. ncbi The risk of simple febrile seizures after immunisation with a new group B meningococcal vaccine, New Zealand
    Paul Stehr-Green
    Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand
    Vaccine 26:739-42. 2008
    ..We concluded that the vaccine is unlikely to induce a heightened risk of SFS...
  6. ncbi The risk of bronchiolitis hospitalisation following administration of a group B meningococcal vaccine in New Zealand
    Paul Stehr-Green
    Department of Epidemiology, University of Washington, Seattle, Washington, USA
    N Z Med J 120:U2746. 2007
    ..We examined more closely the potential association between bronchiolitis hospitalisation and this vaccine...
  7. ncbi The Intensive Vaccines Monitoring Programme (IVMP): an electronic system to monitor vaccine safety in New Zealand
    Michael V Tatley
    New Zealand Pharmacovigilance Centre, University of Otago, Dunedin, New Zealand
    Vaccine 26:2746-52. 2008
    ..We describe the methodology and success factors plus consider the limitations encountered in this system which shows potential as a means for post-marketing vaccine and medicine surveillance in the future...
  8. ncbi Prevalence and risk factors for Chlamydia trachomatis infection in female New Zealand university students
    Michael Baker
    Institute of Environmental Science and Research Limited, Porirua
    N Z Med J 118:U1607. 2005
    ..To measure the prevalence of urogenital Chlamydia trachomatis infection in a sample of sexually active female university students, to identify risk factors associated with infection, and to measure the uptake of screening...